Vontobel Holding Ltd. Purchases 17,040 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Vontobel Holding Ltd. boosted its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 128.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,268 shares of the biotechnology company’s stock after purchasing an additional 17,040 shares during the quarter. Vontobel Holding Ltd.’s holdings in Aclaris Therapeutics were worth $32,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ACRS. Blackstone Inc. raised its holdings in Aclaris Therapeutics by 9,578.7% in the third quarter. Blackstone Inc. now owns 1,261,425 shares of the biotechnology company’s stock worth $8,641,000 after purchasing an additional 1,248,392 shares in the last quarter. Barclays PLC raised its holdings in Aclaris Therapeutics by 174.2% in the third quarter. Barclays PLC now owns 234,150 shares of the biotechnology company’s stock worth $1,603,000 after purchasing an additional 148,761 shares in the last quarter. Trexquant Investment LP bought a new position in Aclaris Therapeutics in the third quarter worth $876,000. Lord Abbett & CO. LLC raised its holdings in Aclaris Therapeutics by 14.0% in the third quarter. Lord Abbett & CO. LLC now owns 453,954 shares of the biotechnology company’s stock worth $3,110,000 after purchasing an additional 55,602 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Aclaris Therapeutics by 7.9% in the third quarter. Assenagon Asset Management S.A. now owns 687,135 shares of the biotechnology company’s stock worth $4,707,000 after purchasing an additional 50,306 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $1.17 on Thursday. Aclaris Therapeutics, Inc. has a one year low of $0.59 and a one year high of $11.12. The stock has a market capitalization of $82.98 million, a PE ratio of -0.92 and a beta of 0.22. The business’s fifty day moving average is $1.22 and its 200 day moving average is $1.83.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. Aclaris Therapeutics had a negative return on equity of 64.56% and a negative net margin of 283.15%. The company had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $3.96 million. As a group, sell-side analysts expect that Aclaris Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

ACRS has been the topic of a number of recent research reports. BTIG Research reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Thursday, January 11th. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Friday, January 12th. Finally, HC Wainwright cut Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of “Hold” and an average price target of $22.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.